March 26, 2021 -- Hitachi and Sophia Genetics are joining forces to bring clinical, genomic, and real-world insights to healthcare providers as well as pharmaceutical and biopharmaceutical companies.
Under the long-term collaboration, the two firms will focus on data-driven precision medicine through the global commercial expansion and development of Hitachi's digital healthcare products, such as its molecular tumor board support service, and Sophia's Data-Driven Medicine (DDM) technology.
DDM is a cloud-based software-as-a-service that uses artificial intelligence (AI) and machine learning to generate insights for clinicians and researchers from multimodal datasets. Those insights lead to improved diagnosis, treatment, and drug development, Sophia said.
In the long run, the two companies will partner on research and development-related new products, they added.